Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices 17969 

(2010) in bulk active pharmaceutical 

ingredient (API) form for distribution to 

the company’s customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Cambrex Charles City, Inc. to 

manufacture the listed basic class of 

controlled substance is consistent with 

the public interest at this time. DEA has 

investigated Cambrex Charles City, Inc. 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: March 21, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–7539 Filed 3–30–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated November 1, 2010, 

and published in the Federal Register 

on November 12, 2010, 75 FR 69464, 

Cerilliant Corporation, 811 Paloma 

Drive, Suite A, Round Rock, Texas 

78665–2402, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the following 

basic classes of controlled substances: 

Drug Schedule 

Cathinone (1235) ........................ I 

Methcathinone (1237) ................. I 

N-Ethylamphetamine (1475) ....... I 

N,N-Dimethylamphetamine 

(1480).

I 

Aminorex (1585) ......................... I 

4-Methylaminorex (cis isomer) 

(1590).

I 

Gamma-Hydroxybutyric acid 

(2010).

I 

Methaqualone (2565) ................. I 

Alpha-ethyltryptamine (7249) ..... I 

Lysergic acid diethylamide 

(7315).

I 

Drug Schedule 

2,5-Dimethoxy-4-(n)- 

propylthiophenethylamine 

(7348).

I 

Marihuana (7360) ....................... I 

Tetrahydrocannabinols (7370) .... I 

Mescaline (7381) ........................ I 

3,4,5-Trimethoxyamphetamine 

(7390).

I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

2,5-Dimethoxy-4- 

ethylamphetamine (7399).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

5-Methoxy-3,4- 

methylenedioxyamphetamine 

(7401).

I 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (7405).

I 

4-Methoxyamphetamine (7411) .. I 

Alpha-methyltryptamine (7432) .. I 

Bufotenine (7433) ....................... I 

Diethyltryptamine (7434) ............ I 

Dimethyltryptamine (7435) ......... I 

Psilocybin (7437) ........................ I 

Psilocyn (7438) ........................... I 

5-Methoxy-N,Ndiisopropyltyptamine (7439).I 

N-Benzylpiperazine (7493) ......... I 

Acetyldihydrocodeine (9051) ...... I 

Benzylmorphine (9052) .............. I 

Codeine-N-oxide (9053) ............. I 

Dihydromorphine (9145) ............. I 

Heroin (9200) .............................. I 

Hydromorphinol (9301) ............... I 

Methyldihydromorphine (9304) ... I 

Morphine-N-oxide (9307) ............ I 

Normorphine (9313) ................... I 

Pholcodine (9314) ...................... I 

Acetylmethadol (9601) ................ I 

Allylprodine (9602) ...................... I 

Alphacetylmethadol except levoalphacetylmethadol (9603).I 

Alphameprodine (9604) .............. I 

Alphamethadol (9605) ................ I 

Betacetylmethadol (9607) ........... I 

Betameprodine (9608) ................ I 

Betamethadol (9609) .................. I 

Betaprodine (9611) ..................... I 

Hydroxypethidine (9627) ............ I 

Noracymethadol (9633) .............. I 

Norlevorphanol (9634) ................ I 

Normethadone (9635) ................ I 

Trimeperidine (9646) .................. I 

Phenomorphan (9647) ................ I 

1–Methyl-4-phenyl-4- 

propionoxypiperidine (9661).

I 

Tilidine (9750) ............................. I 

Para-Fluorofentanyl (9812) ......... I 

3–Methylfentanyl (9813) ............. I 

Alpha-Methylfentanyl (9814) ....... I 

Drug Schedule 

Acetyl-alpha-methylfentanyl 

(9815).

I 

Beta-hydroxyfentanyl (9830) ...... I 

Beta-hydroxy-3-methylfentanyl 

(9831).

I 

Alpha-Methylthiofentanyl (9832) I 

3–Methylthiofentanyl (9833) ....... I 

Thiofentanyl (9835) ..................... I 

Amphetamine (1100) .................. II 

Methamphetamine (1105) .......... II 

Lisdexamfetamine (1205) ........... II 

Phenmetrazine (1631) ................ II 

Methylphenidate (1724) .............. II 

Amobarbital (2125) ..................... II 

Pentobarbital (2270) ................... II 

Secobarbital (2315) .................... II 

Glutethimide (2550) .................... II 

Nabilone (7379) .......................... II 

1-Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................. II 

1- 

Piperidinocyclohexanecarbonitrile (8603).

II 

Alphaprodine (9010) ................... II 

Cocaine (9041) ........................... II 

Codeine (9050) ........................... II 

Dihydrocodeine (9120) ............... II 

Oxycodone (9143) ...................... II 

Hydromorphone (9150) .............. II 

Diphenoxylate (9170) ................. II 

Benzoylecgonine (9180) ............. II 

Ethylmorphine (9190) ................. II 

Hydrocodone (9193) ................... II 

Levomethorphan (9210) ............. II 

Levorphanol (9220) .................... II 

Isomethadone (9226) ................. II 

Meperidine (9230) ...................... II 

Meperidine intermediate-A 

(9232).

II 

Meperidine intermediate-B 

(9233).

II 

Meperidine intermediate-C 

(9234).

II 

Methadone (9250) ...................... II 

Methadone intermediate (9254) II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ......................... II 

Thebaine (9333) ......................... II 

Levo-alphacetylmethadol (9648) II 

Oxymorphone (9652) .................. II 

Noroxymorphone (9668) ............. II 

Racemethorphan (9732) ............. II 

Alfentanil (9737) ......................... II 

Sufentanil (9740) ........................ II 

Tapentadol (9780) ...................... II 

Fentanyl (9801) .......................... II 

The company plans to manufacture 

small quantities of the listed controlled 

substances to make reference standards 

which will be distributed to their 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Cerilliant Corporation to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Cerilliant Corporation to 


wwoods2 on DSK1DXX6B1PROD with NOTICES
17970 Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: March 21, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–7547 Filed 3–30–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Employment and Training 

Administration 

Notice of Funding Opportunity and 

Solicitation for Grant Applications 

(SGA) for the Young Parents 

Demonstration 

AGENCY: Employment and Training 

Administration, Labor. 

ACTION: Notice of Solicitation for Grant 

Applications (SGA). 

Funding Opportunity Number: SGA/ 

DFA PY–10–12 

SUMMARY: The Employment and 

Training Administration (ETA), U.S. 

Department of Labor announces the 

availability of approximately $5.5 

million authorized by the Consolidated 

Appropriations Act of 2010 to support 

applicants in providing intensive 

mentoring services to low-income young 

parents (both mothers and fathers, and 

expectant parents ages 16 to 24) 

participating in workforce development 

programs. Activities under this SGA are 

authorized under Section 171(b) of the 

Workforce Investment Act, which 

allows for demonstration and pilot 

projects for the purpose of developing 

and implementing techniques and 

approaches, and demonstrating the 

effectiveness of specialized methods, in 

addressing employment and training 

needs. 

The complete SGA and any 

subsequent SGA amendments, in 

connection with the Consolidated 

Appropriations Act of 2010 is described 

in further detail on ETA’s Web site at 

http://www.doleta.gov/grants or on 

http://www.grants.gov. The Web sites 

provide application information, 

eligibility requirements, review and 

selection procedures and other program 

requirements governing this solicitation. 

DATES: The closing date for receipt of 

applications is April 29, 2011. 

FOR FURTHER INFORMATION CONTACT: 

Latifa Jeter, 200 Constitution Avenue, 

NW., Room N4716, Washington, DC 

20210; Telephone: 202–693–3553. 

Signed at Washington, DC, this 25th day of 

March, 2011. 

Eric D. Luetkenhaus, 

Grant Officer, Employment and Training 

Administration. 

[FR Doc. 2011–7556 Filed 3–30–11; 8:45 am] 

BILLING CODE 4510–FN–P 

NATIONAL SCIENCE FOUNDATION 

National Science Board; Sunshine Act 

Meetings; Notice 

The National Science Board’s 

Committee on Education and Human 

Resources (CEH), pursuant to NSF 

regulations (45 CFR part 614), the 

National Science Foundation Act, as 

amended (42 U.S.C. 1862n–5), and the 

Government in the Sunshine Act (5 

U.S.C. 552b), hereby gives notice in 

regard to the scheduling of a 

teleconference for the transaction of 

National Science Board business and 

other matters specified, as follows: 

DATE AND TIME: April 7, 2011, 10:30 

a.m.–12 p.m. EST. 

SUBJECT MATTER: Discussion of the 

Committee on Education and Human 

Resources (CEH) STEM education 

prospective ‘‘action items’’ (to be 

developed at the teleconference) and 

discussion of the May 10–11, 2011 CEH 

meeting agenda. 

STATUS: Open. 

LOCATION: This meeting will be held by 

teleconference at the National Science 

Board Office, National Science 

Foundation, 4201 Wilson Blvd., 

Arlington, VA 22230. A room will be 

available for the public to listen-in to 

this meeting held by teleconference at 

Stafford Place I, National Science 

Foundation, 4201 Wilson Blvd., 

Arlington, VA 22230. All visitors must 

contact the Board Office [call 703–292– 

7000 or send an e-mail message to 

nationalsciencebrd@nsf.gov] at least 24 

hours prior to the teleconference for the 

room number and provide name and 

organizational affiliation. All visitors 

must report to the NSF visitor desk 

located in the lobby at the 9th and N. 

Stuart Streets entrance on the day of the 

teleconference to receive a visitor’s 

badge. 

UPDATES AND POINT OF CONTACT: Please 

refer to the National Science Board Web 

site http://www.nsf.gov/nsb for 

additional information and schedule 

updates (time, place, subject matter or 

status of meeting) may be found at 

http://www.nsf.gov/nsb/notices/. Point 

of contact for this meeting is: Matthew 

B. Wilson, National Science Board 

Office, 4201 Wilson Blvd., Arlington, 

VA 22230. Telephone: (703) 292–7000. 

Daniel A. Lauretano, 

Counsel to the National Science Board. 

[FR Doc. 2011–7694 Filed 3–29–11; 11:15 am] 

BILLING CODE 7555–01–P 

NUCLEAR WASTE TECHNICAL 

REVIEW BOARD 

Board Meeting: April 27, 2011— 

Amherst, New York; the U.S. Nuclear 

Waste Technical Review Board Will 

Meet To Discuss the West Valley 

Demonstration Project 

Pursuant to its authority under 

section 5051 of Public Law 100–203, 

Nuclear Waste Policy Amendments Act 

of 1987, the U.S. Nuclear Waste 

Technical Review Board will hold a 

public meeting in Amherst, New York, 

on Wednesday, April 27, 2011, to 

discuss the West Valley Demonstration 

Project (WVDP). Currently planned are 

presentations on the WVDP by 

representatives of the New York State 

Energy Research and Development 

Authority and the U.S. Department of 

Energy’s (DOE) Office of Environmental 

Management. Other issues expected to 

be discussed include previous 

reprocessing and vitrification activities 

at the WVDP; long-term onsite storage of 

vitrified high-level radioactive waste 

(HLW); determination of waste 

classification of the melter from the 

vitrification facility; and the final 

Environmental Impact Statement and 

Record of Decision on decommissioning 

and/or long-term stewardship at the 

WVDP. Also planned are presentations 

and a panel discussion on the 2008–9 

study on Quantitative Risk Assessment 

of the State Licensed Radioactive Waste 

Disposal Area. 

The meeting will be held at the 

Buffalo Marriott Niagara; 1340 

Millersport Highway; Amherst, New 

York 14221; (tel) 716–689–6900; (fax) 

716–689–0483. A block of rooms has 

been reserved at the hotel for meeting 

attendees. To ensure receiving the 

meeting rate, room reservations must be 

made by April 8, 2011. 

Reservations can be made online at 

http://www.buffaloniagaramarriott.com 

using the following procedure: In the 

‘‘Rates & Availability’’ box, enter the 

reservation dates; click ‘‘Special Rates & 


wwoods2 on DSK1DXX6B1PROD with NOTICES